Vital sign monitoring Not Applicable
Conditions
Interventions
Participants will visit the designated research facility for the study visit. On arrival, participants will be assessed for their suitability for the study. An arterial line will be inserted into thei
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Willing and able to give informed consent for participation in the study 2. Men and women aged 18 or over and in generally good health
Exclusion criteria
Exclusion criteria: 1. Allergies to adhesive dressings (such as bio-occlusive dressings or micropore) or local anesthesic (e.g. Lidocaine) 2. Intra-cardiac device (e.g. Permanent pacemaker) or previous wrist arterial line 3. Epilepsy 4. Angina, congenital heart disease or history of severe cardiopulmonary disease 5. History of anaemia (reported in the pre-screening telephone call) or Hb below 100 g/l on first test 6. Resting hypoxaemia (SpO2 <94%) or significant cardiopulmonary disease rendering exposure to alveolar hypoxia unsafe, as determined by the research physician 7. Pregnancy or breastfeeding 8. Clotting disorders and use of antiplatelet or anticoagulant medication (such as Aspirin) 9. Claustrophobia precluding spell in the hypoxic exposure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Specificity and sensitivity of currently available ambulatory vital-sign monitors will be assessed by comparing continuous oxygen saturation, pulse rate and breathing rate data from each ambulatory monitor with arterial blood oxygen saturation measured through blood gas analysis, respiratory rate derived from capnography and pulse rate derived from ‘usual care’ hospital grade pulse oximetry monitoring. Arterial oxygen saturation will be measured at incremental drops in SpO2, up to 80%. Respiratory rate and pulse rate will be measured continuously throughout testing. | — |
Secondary
| Measure | Time frame |
|---|---|
| The effects of movement on data acquisition by currently available ambulatory vital-sign monitors will be assessed by comparing continuous oxygen saturation, pulse rate and breathing rate data from each ambulatory monitor with arterial blood oxygen saturation measured through blood gas analysis, respiratory rate derived from capnography and pulse rate derived from ‘usual care’ hospital grade pulse oximetry monitoring. Arterial oxygen saturation will be measured after each movement is completed. Respiratory rate and pulse rate will be measured continuously throughout testing. | — |
Countries
England, United Kingdom
Contacts
Public ContactSarah Vollam
Outcome results
None listed